Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


BIDMC researchers identify source of preeclampsia


Researchers at Beth Israel Deaconess Medical Center (BIDMC) have identified a protein that leads to the development of preeclampsia, a serious and potentially life-threatening complication of pregnancy.

These findings, which could help lead to the development of diagnostic tools and therapies for this baffling condition, appear in the March 2003 issue of The Journal of Clinical Investigation.

Also known as toxemia, preeclampsia occurs in an estimated 5 percent of all pregnancies, affecting approximately 200,000 women in the U.S. each year. The condition typically develops after the 20th week of pregnancy and in mild cases, is characterized by high blood pressure, edema, and protein in the urine. In severe cases, the condition can rapidly develop into eclampsia, in which the mother suffers serious – and potentially fatal – seizures.

"Currently, there is no treatment for this condition," says the study’s lead author S. Ananth Karumanchi, M.D., of the Renal Division at BIDMC and Instructor of Medicine at Harvard Medical School. "The only management we can offer patients is to deliver the baby and the placenta, which can result in the infant being born prematurely." As a result, preeclampsia is one of the leading causes of maternal and infant mortality in developing countries.

In a normal pregnancy, the developing fetus signals the mother’s body to widen blood vessels to the placenta, which supplies oxygen and nutrients to the fetus. But, for unknown reasons, in women with preeclampsia the blood vessels grow narrower, impeding the flow of blood and oxygen. The diminished oxygen levels apparently set in motion a rapid progression of potentially fatal complications involving the mother’s liver, kidneys, lungs, blood and nervous system.

Scientists have long speculated that the placenta was releasing some unknown factor that was triggering this abnormal course of events. In order to identify this factor, Karumanchi and his colleagues first performed gene expression profiling tests of placental tissue from patients with and without preeclampsia.

The test results showed that a protein known as soluble fms-like tyrosine kinase 1 (sFlt1) was significantly elevated among the preeclampsia patients. With this information in hand, the researchers administered the protein to both pregnant and non-pregnant rats to test whether sFlt1 was at the root of the problem.

"The resulting data was exciting," says Karumanchi. "The rats that were exposed to sFlt1 had distinct clinical and pathological symptoms of preeclampsia, demonstrating for the first time a clear cause and effect relationship between this protein and this disease."

What is apparently happening, he explains, is that sFlt1 is binding to and "mopping up" another group of proteins, known as angiogenic factors. "Vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) exist to promote angiogenesis, the growth and health of small blood vessels," he explains. VEGF has, in fact, been shown to promote tumor growth among cancer patients and is therefore the target of anti-angiogenic therapies being developed for the treatment of some malignancies.

Among preeclampsia patients, says Karumanchi, the diminished levels of VEGF and PIGF caused by the actions of sFlt1 affect the health of the mother’s small blood vessels, and ultimately lead to the telltale symptoms of preeclampsia.

"These findings provide us with an important piece of information as we work to develop strategies to treat preeclampsia," notes Karumanchi. "We’re obviously a number of years away from being able to put these to use in humans but these results are an important step in the process." Furthermore, adds study coauthor Vikas Sukhatme, M.D., Ph.D., this study has important implications for the use of anti-angiogenic therapies in the treatment of cancer.

Study coauthors include Sharon Maynard, M.D., Jiang-Yong Min, M.D., Jaime Merchan, M.D., Kee-Hak Lim, M.D., Jianyi Li, Ph.D., Susanta Mondal, Ph.D., Towia Libermann, Ph.D., James Morgan, M.D., Ph.D., Frank Sellke, M.D., Isaac Stillman, M.D., Franklin Epstein, M.D., and Vikas Sukhatme, M.D., Ph.D., who represent the Departments of Medicine, Surgery, Pathology and Obstetrics and Gynecology at Beth Israel Deaconess Medical Center.

The study was supported by grants from the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the American Society of Nephrology, and support from Beth Israel Deaconess Medical Center.

Beth Israel Deaconess Medical Center is a major patient care, research and teaching affiliate of Harvard Medical School and a founding member of CareGroup Healthcare System. The Department of Obstetrics and Gynecology at BIDMC delivers 5,000 infants each year and specializes in the care of high-risk pregnant women, including preeclampsia patients. Beth Israel Deaconess is the third largest recipient of National Institutes of Health funding among independent U.S. teaching hospitals.

Bonnie Prescott | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Modular safety concept increases flexibility in plant conversion

22.03.2018 | Trade Fair News

New interactive map shows climate change everywhere in world

22.03.2018 | Earth Sciences

New technologies and computing power to help strengthen population data

22.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>